Pacer Advisors Inc. Acquires 26,044 Shares of Roivant Sciences Ltd. $ROIV

Pacer Advisors Inc. increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 37.1% in the first quarter, Holdings Channel reports. The institutional investor owned 96,303 shares of the company’s stock after buying an additional 26,044 shares during the period. Pacer Advisors Inc.’s holdings in Roivant Sciences were worth $2,668,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in ROIV. SBI Securities Co. Ltd. grew its position in Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP increased its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new position in Roivant Sciences in the 4th quarter valued at $47,000. Parallel Advisors LLC raised its holdings in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its holdings in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after acquiring an additional 2,665 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ROIV. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. HC Wainwright boosted their price target on Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Friday. Citigroup upped their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.77.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $36.34 on Friday. The business has a fifty day moving average price of $33.13 and a two-hundred day moving average price of $29.46. The stock has a market capitalization of $26.14 billion, a PE ratio of -68.57 and a beta of 1.12. Roivant Sciences Ltd. has a fifty-two week low of $10.90 and a fifty-two week high of $37.00.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Guggenheim raised its price target to $42 from $36 and assigned a “Buy” rating. The revision implies meaningful upside and provides a clear near-term bullish catalyst for Roivant Sciences (ROIV). Benzinga analyst upgrade
• Positive Sentiment: Roivant said it expects to launch brepocitinib for dermatomyositis by the end of September, a milestone that could improve confidence in the company’s commercialization strategy. It also plans to target cutaneous sarcoidosis, with Phase 3 data expected in 2028. Brepocitinib launch and pipeline update
• Positive Sentiment: Roivant’s subsidiary Immunovant reported that IMVT-1402 development remains on schedule across several autoimmune indications, including Graves’ disease and myasthenia gravis. Its cash balance is expected to fund operations through a potential Graves’ disease launch, reducing near-term financing concerns. Immunovant corporate update

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at $53,489,169.08. This represents a 11.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the completion of the sale, the director directly owned 13,701,546 shares in the company, valued at $473,388,414.30. This trade represents a 5.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 2,055,913 shares of company stock valued at $69,639,633. Corporate insiders own 8.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.